Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DPV-001 by UbiVac for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
DPV-001 is under clinical development by UbiVac and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma....